Similar Papers

Paper Title
Journal
Date
Author
Abstract PS16-06: Tumor-infiltrating lymphocytes and pathologic response to neoadjuvant chemotherapy with the addition of platinum and pembrolizumab in TNBC: A single-center real-world study
Min Ji Kim ... Yoonwon Kook
Cancer Research | VOL. 84
Min Ji Kim, et. al.Min Ji Kim ... Yoonwon Kook
02 May 2024
Abstract 1149: Spatial transcriptomic analysis of tumor microenvironment in patients with triple negative breast cancer with residual disease after neoadjuvant chemotherapy with immune checkpoint inhibitor
Ji-Yeon Kim ... Byung Joo Chae
Cancer Research | VOL. 84
Ji-Yeon Kim, et. al.Ji-Yeon Kim ... Byung Joo Chae
22 Mar 2024
Abstract P4-06-11: Pathologic Complete Response in Triple Negative Breast Cancer of Black vs White Patients in the Post-Keynote 522 Era
Melanie Sheen ... Victoria Chung
Cancer Research | VOL. 83
Melanie Sheen, et. al.Melanie Sheen ... Victoria Chung
01 Mar 2023
Abstract B13: High-risk patients found affected with breast cancer during a multimodality screening program: Triple negative versus non-triple negative breast cancers
Franca Podo ... Francesco Sardanelli
Cancer Prevention Research | VOL. 5
Franca Podo, et. al.Franca Podo ... Francesco Sardanelli
01 Nov 2012
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Table of Contents
-
Annals of Oncology | VOL. 36
--
01 Jan 2025
Editorial Board
-
Annals of Oncology | VOL. 36
--
01 Jan 2025
89P Spatial analysis using MultiOmyx hyperplex assay reveals high prevalence of mature tertiary lymphoid structure (TLS) and PDL1 expression in the MSI-high colorectal carcinoma (CRC)
Q Au ... V Chizhevsky
Annals of Oncology | VOL. 35
Q Au, et. al.Q Au ... V Chizhevsky
01 Dec 2024
276MO Epidemiology, treatment (tx) patterns, and clinical outcomes of patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC) in Taiwan: A retrospective cohort study
C-T Wu ... L-N Chien
Annals of Oncology | VOL. 35
C-T Wu, et. al.C-T Wu ... L-N Chien
01 Dec 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.